Evidence map›Paper›PMID 30167889›Full record

ReviewJournal of cancer research and clinical oncology2018

Role of ferroptosis in hepatocellular carcinoma.

Jianhua Nie, Binlin Lin, Meng Zhou, Li Wu, Tongsen Zheng

Open access · greenAbstract readReview
In one paragraph

Review in Journal of cancer research and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 157 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
157citing papers in PubMed, 2 pooled it
13.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

157 citing papers in PubMed, 2 syntheses or guidelines pooled it, 254 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Targeting ferroptosis to overcome drug resistance in gastrointestinal cancers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

97 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jianhua NieDepartment of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, 150040, Heilongjiang, People's Republic of China.
Binlin LinDepartment of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, 150040, Heilongjiang, People's Republic of China.
Meng ZhouDepartment of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, 150040, Heilongjiang, People's Republic of China.
Li WuDepartment of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, 150040, Heilongjiang, People's Republic of China.
Tongsen ZhengDepartment of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, 150040, Heilongjiang, People's Republic of China. zhengtongsen@hotmail.com.ORCID http://orcid.org/0000-0002-7539-3924
Harbin Medical University · CN

Funding

China Postdoctoral Science Foundation No. 2014M560271China Postdoctoral Science Foundation No. 2015T80369Heilongjiang Postdoctoral Science Foundation No. LBH-TZ1615Heilongjiang Postdoctoral Science Foundation No. LBH-Z14142the Fok Ying Tung Education Foundation No. 151037the National Natural Scientific Foundation of China No. 81302060the National Natural Scientific Foundation of China No. 81472322the National Natural Scientific Foundation of China No. 81672930the Natural Science Foundation of Heilongjiang Province LC201437/H1617
6 · The paper itself

Abstract

purposeHepatocellular carcinoma (HCC) is a complicated disease with low survival rate due to frequent recurrence and the lack of efficient therapies. For advanced HCC, sorafenib, as the only approved first-line drug for HCC, improves the survival to some extent, but depressingly with severe adverse effects and emerging resistance conditions, which cause a poor prognosis. Ferroptosis is a new recognized way of non-apoptosis-regulated cell death, characterized by the iron-dependent accumulation of lipid hydroperoxides, showing a tremendous promising in the therapy of cancer, especially in HCC. To provide ideas for the diagnosis and treatment of HCC, we summarized the role of ferroptosis in HCC.

methodsThe relevant literature from PubMed is reviewed in this article.

resultsInterestingly enough, investigators have found sorafenib can induce ferroptosis in HCC. Moreover, recent researches reported increasing pathways and mechanisms related to ferroptosis in HCC such as TP53 and Rb, and strategies to improve sorafenib resistance by targeting ferroptosis. In addition, other drugs were reported to induce ferroptosis in HCC such as erastin and showed good efficacy in vivo and in vitro.

conclusionIn this review, we summarize pathways and mechanisms of ferroptosis in HCC and other digestive system neoplasms such as gastric cancer, pancreatic cancer and colorectal cancer and point out the trends of ferroptosis in HCC.

Indexed as

CarcinogenesisCell DeathAnimalsCarcinoma, HepatocellularDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticGenetic VariationHumansLipid MetabolismLiver NeoplasmsSignal TransductionSorafenibSorafenibFerroptosisHepatocellular carcinomaIronLipid metabolismSorafenibTherapy

Identifiers

PMID30167889
PMCPMC11813439
OpenAlexW2888144978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.